Prescient Therapeutics: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 39: | Line 39: | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 23:51, 17 March 2025
Prescient Therapeutics is a clinical-stage oncology company that specializes in the development of novel drugs that provide treatment options for a variety of cancer types. The company's primary focus is on the development of personalized therapies that target the specific needs of individual patients.
History[edit]
Prescient Therapeutics was founded with the aim of developing and commercializing novel, targeted therapies for the treatment of a range of different cancers. The company's approach is based on the understanding that each patient's cancer is unique and requires a personalized treatment strategy.
Research and Development[edit]
Prescient Therapeutics' research and development efforts are focused on the discovery and development of novel, targeted therapies for the treatment of cancer. The company's pipeline includes a number of promising drug candidates that are currently in various stages of clinical development.
PTX-100[edit]
PTX-100 is a first-in-class compound that blocks the RhoA and RhoC proteins, which are involved in cancer cell growth and survival. PTX-100 has shown promising results in early-stage clinical trials for the treatment of certain types of leukemia and lymphoma.
PTX-200[edit]
PTX-200 is a novel phosphatidylinositol 3-kinase (PI3K) inhibitor that has shown potential in preclinical and early-stage clinical trials for the treatment of certain types of breast cancer, ovarian cancer, and leukemia.
Clinical Trials[edit]
Prescient Therapeutics is currently conducting a number of clinical trials to evaluate the safety and efficacy of its drug candidates. These trials are being conducted in collaboration with leading cancer centers and research institutions around the world.
Future Directions[edit]
Prescient Therapeutics continues to explore new avenues for the development of novel, targeted therapies for the treatment of cancer. The company's ongoing research and development efforts are aimed at identifying new drug candidates and advancing its existing pipeline through clinical development.
See Also[edit]
